[HTML][HTML] Korean practice guidelines for gastric cancer 2022: an evidence-based, multidisciplinary approach
TH Kim, IH Kim, SJ Kang, M Choi, BH Kim… - Journal of Gastric …, 2023 - ncbi.nlm.nih.gov
Gastric cancer is one of the most common cancers in Korea and the world. Since 2004, this
is the 4th gastric cancer guideline published in Korea which is the revised version of …
is the 4th gastric cancer guideline published in Korea which is the revised version of …
Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: a …
Introduction: Atezolizumab-bevacizumab is the new standard of care for first-line treatment of
advanced hepatocellular carcinoma (HCC). However, the optimal sequence of therapy after …
advanced hepatocellular carcinoma (HCC). However, the optimal sequence of therapy after …
[HTML][HTML] A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair–Deficient/Microsatellite Instability–High or POLE-Mutated Metastatic or …
JH Kim, SY Kim, JY Baek, YJ Cha, JB Ahn… - Cancer Research and …, 2020 - ncbi.nlm.nih.gov
Purpose We evaluated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in
patients with metastatic or unresectable colorectal cancer (mCRC) with mismatch repair …
patients with metastatic or unresectable colorectal cancer (mCRC) with mismatch repair …
[HTML][HTML] Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 …
JH Kim, MH Ryu, YS Park, J Ma, SY Lee, D Kim… - BMC cancer, 2022 - Springer
Purpose The phase 3 ATTRACTION-2 study demonstrated that nivolumab monotherapy
improved survival compared to placebo in patients with pretreated advanced gastric cancer …
improved survival compared to placebo in patients with pretreated advanced gastric cancer …
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase …
AO Siefker-Radtke, N Matsubara, SH Park… - Annals of …, 2024 - Elsevier
Background Erdafitinib is an oral pan-fibroblast growth factor receptor (FGFR) tyrosine
kinase inhibitor approved to treat locally advanced/metastatic urothelial carcinoma (mUC) in …
kinase inhibitor approved to treat locally advanced/metastatic urothelial carcinoma (mUC) in …
[HTML][HTML] Real-world efficacy data and predictive clinical parameters for treatment outcomes in advanced esophageal squamous cell carcinoma treated with immune …
Purpose This study aimed to evaluate the real-world efficacy of immune checkpoint
inhibitors (ICIs), and to identify clinicolaboratory factors to predict treatment outcomes in …
inhibitors (ICIs), and to identify clinicolaboratory factors to predict treatment outcomes in …
[HTML][HTML] Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study
S Bae, YJ Kim, M Kim, JH Kim, SC Yun… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background While some recent studies have reported the development of tuberculosis (TB)
in patients exposed to immune checkpoint inhibitors (ICIs), there is limited evidence to date …
in patients exposed to immune checkpoint inhibitors (ICIs), there is limited evidence to date …
[HTML][HTML] A phase II study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous dalteparin for cancer-associated venous …
Simple Summary This prospective phase II trial evaluated the safety and efficacy of direct
oral anticoagulants (DOACs) versus subcutaneous dalteparin for cancer-associated venous …
oral anticoagulants (DOACs) versus subcutaneous dalteparin for cancer-associated venous …
Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors
Background Immune checkpoint inhibitors (ICI) have become an important treatment option
for non-small cell lung cancer (NSCLC). We aimed to evaluate the clinical impact of …
for non-small cell lung cancer (NSCLC). We aimed to evaluate the clinical impact of …
Real‐world utility of next‐generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma
JH Kim, S Yoon, DH Lee, SJ Jang, SM Chun… - Cancer …, 2021 - Wiley Online Library
Purpose This study investigated the clinical utility of next‐generation sequencing (NGS) for
detection of genetic alterations and its implications on treatment of lung adenocarcinoma in …
detection of genetic alterations and its implications on treatment of lung adenocarcinoma in …